LB Pharmaceuticals appoints Dr. Robert Lenz to Board and promotes Gad Soffer to COO

LB PHARMACEUTICALS INC

Robert Lenz, M.D., Ph.D., appointed to Board as Class I director; brings over 20 years of neuroscience R&D experience.
Lenz receives $40,000 annual retainer, $5,000 for Nominating Committee, and initial option grant of 20,000 shares.
Gad Soffer promoted from Chief Business Officer to Chief Operating and Business Officer, effective March 4, 2026.
Soffer's annual base salary increased to $505,000 with target bonus of 40% of base salary.
Lenz previously served as EVP R&D at Neumora Therapeutics and SVP Global Development at Amgen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.